Over 200 Total Lots Up For Auction at One Location - UT 06/15

Military University Hospital Prague selects ViewRay's MRIdian MR-guided radiotherapy system

Press releases may be edited for formatting or style | March 07, 2023 MRI
DENVER, March 7, 2023 /PRNewswire/ -- ViewRay, Inc. (NASDAQ: VRAY) today announced the Czech Ministry of Health has approved the purchase of ViewRay's MRIdian system to bring advanced MRI-guided radiation therapy to treat its cancer patients at the Military University Hospital Prague in the Czech Republic. This is the first and only hospital to offer the precision of MRIdian Stereotactic MRI-guided Adaptive Radiotherapy (SMART) in the Czech Republic. The purchase was co-financed by the REACT-EU financial instrument and the founder's contribution, the Ministry of Defense of the Czech Republic.

The Military University Hospital Prague is a training, educational, and professional medical facility of the Army of the Czech Republic. It provides comprehensive health care at the level of teaching hospitals to members of the Czech Army, war veterans, and people in and outside the region. The hospital has 10 clinics and 20 specialized departments, many collaborating to train medical students in medical schools. The hospital is equipped with modern technology and reflects contemporary trends in medicine.

"The acquisition of MRIdian marks another significant shift in the treatment of cancer patients throughout the Czech Republic and provides a highly sophisticated and gentle cancer treatment option at a world-class level," said Professor Miroslav Zavoral, M.D., Ph.D., Director of the Military University Hospital Prague. "The system offers precision with unparalleled MRI-quality visualization, real-time tissue tracking, and automatic beam control while allowing for adaptation during the planning and treatment process. The system will significantly improve the accuracy of radiation delivery in problematic areas of the abdominal cavity and mediastinum, thus enabling better-quality treatment. In addition, we can expect a higher probability of local tumor control and a longer survival time for cancer patients treated here."
DOTmed text ad

New Fully Configured 80-slice CT in 2 weeks with Software Upgrades for Life

For those who need to move fast and expand clinical capabilities -- and would love new equipment -- the uCT 550 Advance offers a new fully configured 80-slice CT in up to 2 weeks with routine maintenance and parts and Software Upgrades for Life™ included.

The MRIdian system provides oncologists with outstanding anatomical visualization through diagnostic-quality MR images and the ability to adapt a radiation therapy plan to the targeted cancer with the patient on the table. This combination allows physicians to define tight treatment margins to avoid unnecessary radiation exposure of vulnerable organs-at-risk and healthy tissue and allows the delivery of ablative radiation doses in five or fewer treatment sessions without relying on implanted markers. MRIdian enables automatic gating of the radiation beam if the target moves outside the user-defined margins by providing continuous real-time tracking of the target and organs at risk. This allows for delivering the prescribed dose to the target while sparing surrounding healthy tissue and critical structures. This results in minimizing toxicities typically associated with conventional radiation therapy.

To date, over 29,000 patients have been treated with MRIdian. Currently, 57 MRIdian systems are installed at hospitals around the world, where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. For a list of treatment centers, please visit: https://viewray.com/find-mridian-mri-guided-radiation-therapy/

About ViewRay
ViewRay, Inc. (Nasdaq: VRAY) designs, manufactures and markets the MRIdian® MRI-Guided Radiation Therapy System. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purpose-built to address specific challenges, including beam distortion, skin toxicity, and other concerns that potentially may arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.

You Must Be Logged In To Post A Comment